Cardiff Oncology (NASDAQ:CRDF) Now Covered by Analysts at Jefferies Financial Group

Jefferies Financial Group began coverage on shares of Cardiff Oncology (NASDAQ:CRDF) in a research note issued to investors on Tuesday, MarketBeat.com reports. The brokerage issued a hold rating and a $3.50 price target on the stock.

A number of other brokerages have also issued reports on CRDF. HC Wainwright boosted their price target on Cardiff Oncology from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. William Blair reiterated an “outperform” rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.88.

Cardiff Oncology Price Performance

Cardiff Oncology stock opened at $3.20 on Tuesday. The company has a market cap of $212.90 million, a PE ratio of -3.48 and a beta of 1.61. Cardiff Oncology has a 12 month low of $2.01 and a 12 month high of $5.64. The company has a fifty day moving average price of $3.11 and a two-hundred day moving average price of $3.56.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 8,308.50% and a negative return on equity of 76.45%. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.09 million. Equities research analysts anticipate that Cardiff Oncology will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CRDF. Rhumbline Advisers boosted its position in Cardiff Oncology by 18.8% during the first quarter. Rhumbline Advisers now owns 63,142 shares of the company’s stock valued at $198,000 after purchasing an additional 9,970 shares during the last quarter. Belpointe Asset Management LLC bought a new position in shares of Cardiff Oncology in the first quarter valued at approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Cardiff Oncology by 50.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,319 shares of the company’s stock valued at $108,000 after buying an additional 11,497 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Cardiff Oncology by 183.2% in the first quarter. Jacobs Levy Equity Management Inc. now owns 396,118 shares of the company’s stock valued at $1,244,000 after purchasing an additional 256,264 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Cardiff Oncology by 11.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,445,000 shares of the company’s stock valued at $4,537,000 after buying an additional 152,692 shares during the last quarter. 16.29% of the stock is owned by institutional investors and hedge funds.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.